Literature DB >> 3086431

HD39 (B3), a B lineage-restricted antigen whose cell surface expression is limited to resting and activated human B lymphocytes.

B Dörken, G Moldenhauer, A Pezzutto, R Schwartz, A Feller, S Kiesel, L M Nadler.   

Abstract

The B cell-restricted antigen HD39, whose cell surface expression is limited to resting and activated human B lymphocytes, is described in this report. The monoclonal antibody HD39 detects a two-chain glycoprotein with apparent molecular weights of 130,000 and 140,000. During B cell ontogeny, HD39 is first expressed in the cytoplasm of bone marrow derived pre-B cells, then appears on the cell surface of sIgM+ B cells, and finally on the majority of sIgM+ sIgD+ resting B cells. After activation in vitro, the expression of HD39 on the cell surface first increases, and then the antigen is lost as cells begin to differentiate. HD39 is weakly expressed on very few non-T cell ALL and B cell CLL, on approximately 50% of B cell lymphomas, and not on Waldenström's macroglobulinemias and myelomas. In contrast, it is strongly expressed on all hairy cell leukemias. Its limited cell surface expression in B cell ontogeny suggests that HD39 may be important in the events that regulate the activation of the human resting B lymphocytes.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3086431

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  48 in total

Review 1.  B cell inhibitory receptors and autoimmunity.

Authors:  Nicholas R Pritchard; Kenneth G C Smith
Journal:  Immunology       Date:  2003-03       Impact factor: 7.397

2.  Regulated secretion and purification of recombinant antibodies in E. coli.

Authors:  S Dübel; F Breitling; I Klewinghaus; M Little
Journal:  Cell Biophys       Date:  1992 Aug-Dec

Review 3.  Inotuzumab: from preclinical development to success in B-cell acute lymphoblastic leukemia.

Authors:  Joseph Wynne; David Wright; Wendy Stock
Journal:  Blood Adv       Date:  2019-01-08

4.  A kindred with mutant IKAROS and autoimmunity.

Authors:  Erika Van Nieuwenhove; Josselyn E Garcia-Perez; Christine Helsen; Princess D Rodriguez; Pauline A van Schouwenburg; James Dooley; Susan Schlenner; Mirjam van der Burg; Els Verhoeyen; Rik Gijsbers; Seth Frietze; Hilde Schjerven; Isabelle Meyts; Frank Claessens; Stephanie Humblet-Baron; Carine Wouters; Adrian Liston
Journal:  J Allergy Clin Immunol       Date:  2018-04-27       Impact factor: 10.793

Review 5.  Investigational immunotherapeutics for B-cell malignancies.

Authors:  Alfonso Quintás-Cardama; William Wierda; Susan O'Brien
Journal:  J Clin Oncol       Date:  2010-01-04       Impact factor: 44.544

Review 6.  Molecular characterization of CD34+ human hematopoietic progenitor cells.

Authors:  W Knapp; H Strobl; C Scheinecker; C Bello-Fernandez; O Majdic
Journal:  Ann Hematol       Date:  1995-06       Impact factor: 3.673

7.  Epitope specificity of the anti-(B cell lymphoma) monoclonal antibody, LL2.

Authors:  R Stein; E Belisle; H J Hansen; D M Goldenberg
Journal:  Cancer Immunol Immunother       Date:  1993-10       Impact factor: 6.968

8.  Surrogate target cells expressing surface anti-idiotype antibody for the clinical evaluation of an internalizing CD22-specific antibody.

Authors:  Shui-On Leung; Kai Gao; Guang Yu Wang; Benny Ka-Wa Cheung; Kwan-Yeung Lee; Qi Zhao; Wing-Tai Cheung; Jun Zhi Wang
Journal:  MAbs       Date:  2015       Impact factor: 5.857

9.  The role of cell maturation in the generation of phenotypic heterogeneity in B-cell chronic lymphocytic leukaemia.

Authors:  A H Maddy; A Sanderson; M J Mackie; S K Smith
Journal:  Immunology       Date:  1989-11       Impact factor: 7.397

10.  Considering B7-CD28 as a family through sequence and structure.

Authors:  Sean M West; Xiaodi A Deng
Journal:  Exp Biol Med (Maywood)       Date:  2019-06-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.